Subchondral Bone Injections for the Treatment of Knee Osteoarthritis

Document Type : In Brief

Author

Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain

10.22038/abjs.2025.88678.4020

Abstract

The existing literature on whether subchondral bone injections in knee OA is advisable for relieving patient pain is minimal and the level of evidence is low. A recent case series (2023) analyzed 30 individuals with knee OA (Kellgren-Lawrence 2-3). It showed that combined intraarticular and subchondral BMAC (bone marrow aspirate concentrate injections) provided clinical and imaging benefits up to 24 months for the treatment of symptomatic knee OA, with a low failure rate, and a significant reduction of bone marrow edema. Besides, VAS (visual analog scale) pain worsened at the final follow-up, although remained lower compared to the baseline value. Although some studies mention that subchondral bone injections can relieve pain in mild/moderate knee OA, it does not seem reasonable to advise it until better-designed research can confirm the preliminary studies discussed in this article.

Grade of evidence: III

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 14 December 2025
  • Receive Date: 01 June 2025
  • Revise Date:
  • Accept Date: 23 June 2025